I think you'll find the original dosing comments, ahem, enlightening:
The primary end-point for the clinical trial will be to assess safety and tolerance of TT-034 in HCV-infected patients. Benitec expects to report a preliminary assessment of safety data to the ASX throughout the clinical trial on the following basis:
Notwithstanding this anticipated schedule, the Company will provide an update to the ASX at any time should a material event occur that relates to the clinical trial.
- Notification that the second patient in the trial has been dosed;
- Dosing of the first patient in the second cohort, along with comments on the first cohort;
- Dosing of the first patient in the third cohort, along with comments on the second cohort;
- Dosing of the first patient in the fourth cohort, along with comments on the third cohort; and
- Dosing of the first patient in the fifth cohort, along with comments on the fourth cohort.
http://www.irasia.com/listco/au/benitec/press/p140711.htm
- Forums
- ASX - By Stock
- BLT
- Ann: App 4E / Full Year Statutory Accounts
Ann: App 4E / Full Year Statutory Accounts, page-46
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online